Roche looks set to make further in-roads into the spinal muscular atrophy (SMA) market with Evrysdi, with new data backing up its use in pre-symptomatic babies as well as older patients.
The company has just unveiled updated interim data suggesting its oral therapy Evrysdi (risdoplam) can achieve similar results to Biogen’s...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
